Search Thought Leadership


To refine your search select a single option or a combination of options:

reset
 

THOUGHT LEADERSHIP

GC Survey
March 29, 2021
Under Investigation: A GC Guide to White Collar and Sanctions Trends in 2021
Latham has partnered with The Legal 500 US/General Counsel magazine on its inaugural white collar special edition survey – a leading insight into the most critical regulatory concerns shared among GCs of top global companies.
Share
view
Displaying Thought Leadership item(s) about Healthcare & Life Sciences
1/2/3/4/5Next 213 results
 
  • February 19, 2021
     
    life_sciences_003 Latham lawyers Eveline Van Keymeulen and Jeanne Fabre discuss essential rules on medicines and medical devices under the French regulatory regime, for the Life Sciences Law Review.
     
    Share
    view
  • September 30, 2020
     
    Legal books In an article for Bloomberg Law, partners Blair Connelly and Colleen Smith and associate Cindy Guan, explore patterns emerging in securities litigation in the age of the pandemic.
     
    Share
    view
  • September 21, 2020
     
    Pills Healthcare artificial intelligence is a promising sector for PE investors that requires careful navigation, particularly given divergent regulatory approaches.
     
    Share
    view
  • May 28, 2020
     
    Life Sciences Last year proved to be another record period for securities class actions, with a 13% increase in cases filed compared with 2018, and a 24% increase in claims brought against life sciences companies compared with 2018, write partners Michele Johnson and Colleen Smith in In Vivo.
     
    Share
    view
  • June 19, 2019
     
    Medical files Healthcare entities should assess whether Federal Law No. 2 of 2019 applies to their practices and plan for compliance.
     
    Share
    view
 
1/2/3/4/5Next
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.